Edition:
United Kingdom

People: Atara Biotherapeutics Inc (ATRA.OQ)

ATRA.OQ on NASDAQ Stock Exchange Global Select Market

31.69USD
22 Apr 2019
Change (% chg)

$-0.17 (-0.53%)
Prev Close
$31.86
Open
$31.65
Day's High
$32.03
Day's Low
$30.75
Volume
100,230
Avg. Vol
168,086
52-wk High
$54.45
52-wk Low
$27.85

Gallagher, Carol 

Dr. Carol G. Gallagher, Pharm.D. is the Lead Independent Director of the Company. Since October 2014, Dr. Gallagher has served as a partner with New Enterprise Associates, a venture capital firm. Prior to joining New Enterprise Associates, Dr. Gallagher served as a venture partner with Frazier Healthcare, a venture capital firm, from October 2013 to September 2014. Dr. Gallagher served as the President and Chief Executive Officer of Calistoga Pharmaceuticals, a biopharmaceutical company, from 2008 to 2011, when the company was acquired by Gilead Sciences. From 2007 to 2008, Dr. Gallagher was the President and Chief Executive Officer of Metastatix, Inc., a biopharmaceutical company. Prior to that time starting in 1989, she served in various roles at pharmaceutical companies Eli Lilly, Amgen, Agouron Pharmaceuticals, Pfizer, Biogen Idec Pharmaceuticals, CancerVax and Anadys Pharmaceuticals. Dr. Gallagher attended Vanderbilt University and received B.S. and Doctor of Pharmacy degrees from the University of Kentucky.

Basic Compensation

Total Annual Compensation, USD 72,500
Restricted Stock Award, USD 96,150
Long-Term Incentive Plans, USD --
All Other, USD 176,789
Fiscal Year Total, USD 345,439

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Isaac Ciechanover

3,366,820

Utpal Koppikar

--

Joseph Newell

1,641,820

Christopher Haqq

3,298,020

Mitchall Clark

1,402,910

Gad Soffer

3,098,040
As Of  31 Dec 2017